Stockreport

Immatics Announces Pricing of $150 Million Public Offering

Immatics N.V. - Ordinary Shares  (IMTX) 
PDF Houston, Texas and Tuebingen, Germany, October 10, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery an [Read more]